Public Disclosure from Dr. Howard Urnovitz

1. Public Disclosure from Dr. Howard Urnovitz One life, one test FBB, Inc.

2. The Opportunity: Medicine is now curing major diseases The Problem: Too few patients benefit because monitoring the therapy takes months to evaluate and at too high a cost The Solution: Real-time liquid biopsies blood tests to better guide medical decision making

3. LIQUID BIOPSY 1996, Dr. Howard B. Urnovitz was the first to matchgeneticmaterial in the blood to the Human Genome. Thisdiagnosticapproachisnow referred to as a Liquid Biopsy, whichcurrentlyis a US $30 billioncancermedicaldevice market.

4. Dr Urnovitz presented his cancer liquid biopsy monitoring test at the Royal Society of Medicine 2015, London UK. This monitoring test captures first mover advantage of the 40% cancer liquid biopsy market.

5. Liquid Biopsy for Inflammatory Diseases Dr. Urnovitz presented his plan for commercializing blood tests using artificial intelligence and deep machine learning on plasma RNA. These personalized blood tests or liquid biopsies will be used for monitoring treatments in inflammatory disease. These new blood tests will create liquid biopsy markets in neurology and auto-immune diseases Dr Urnovitz presenting on January 27, 2019 at the Deep Learning conference near Munich, Germany

6. The expertise of RNA biologists coupled with the new tools of deep machine learning means more quality of life for all of us. Dr Howard Urnovitz - Liquid Biopsy Pioneer One life, one test